Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NOS1 | P29475 | 3/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 2/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | LTK | P29376 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21863628 | 0.80 | GLA (0.58) | GLAL3MBTL1NOS1HDAC6RET | |
| SCHEMBL20239491 | 0.77 | GLA (0.63) | GLAL3MBTL1NOS1HDAC6RET | |
| SCHEMBL2611043 | 0.73 | NOS1 (0.53) | GLAL3MBTL1NOS1RETCDK5 | |
| SCHEMBL27762041 | 0.72 | GLA (0.54) | GLAL3MBTL1NOS1HDAC6RET | |
| SCHEMBL11577556 | 0.72 | GLA (0.54) | GLAL3MBTL1NOS1HDAC6RET | |
| SCHEMBL24678700 | 0.72 | NOS1 (0.49) | GLAL3MBTL1NOS1HDAC6RET | |
| SCHEMBL21600866 | 0.72 | JAK2 (0.58) | NOS1CYP1A2CYP3A4HPGDCYP2C19 | |
| SCHEMBL3007529 | 0.72 | GLA (0.50) | GLAL3MBTL1NOS1HDAC6RET | |
| SCHEMBL22001247 | 0.71 | NR3C1 (0.56) | ZAP70TRPV1 | |
| SCHEMBL23796148 | 0.71 | NOS1 (0.52) | GLAL3MBTL1NOS1RETCDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197406-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS FOR USING SAME | 1ST Biotherapeutics, Inc. (KR) | 2025-06-19 | — | — | US | disclosed |
| US-11649255-B2 | Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same | 1ST Biotherapeutics, Inc. (KR) | 2023-05-16 | — | — | US | disclosed |
| US-20220098193-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME | 1ST Biotherapeutics, Inc. | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649255-B2 | Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same | IP6K1, HIPK1, IP6K3 | GLA 3444/4885L3MBTL1 2871/4885NOS1 2864/4885 |
| US-20220098193-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME | IP6K1, HIPK1, IP6K3 | GLA 3444/4885L3MBTL1 2871/4885NOS1 2864/4885 |
| US-20250197406-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS FOR USING SAME | IP6K1, HIPK1, IP6K3 | GLA 3590/4885L3MBTL1 3048/4885NOS1 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.